Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1076362

O=C(O)C(F)(F)F.O=S1(=O)Nc2cccc(c2)Nc2nc(ncc2Cl)Nc2cccc1c2

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 11/20 0.64
JAK1 P23458 11/20 0.64
JAK3 P52333 11/20 0.64
TYK2 P29597 10/20 0.64
EPHA2 P29317 6/20 0.46
GAK O14976 5/20 0.46
ABL1 P00519 5/20 0.46
FGFR1 P11362 5/20 0.46
FLT1 P17948 5/20 0.46
EPHA4 P54764 5/20 0.46
CDK1 P06493 1/20 0.44
CDK2 P24941 1/20 0.44
KDR P35968 1/20 0.44
ALK Q9UM73 6/20 0.40
STK4 Q13043 1/20 0.39
STK3 Q13188 1/20 0.39
STK26 Q9P289 1/20 0.39
STK24 Q9Y6E0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1074026 1.00 JAK2 (0.64) JAK2JAK1JAK3TYK2EPHA2
SCHEMBL4363052 0.90 JAK2 (0.76) JAK2JAK1JAK3TYK2EPHA2
SCHEMBL4361179 0.90 JAK2 (0.76) JAK2JAK1JAK3TYK2EPHA2
Trifluoroacetic Acid SCHEMBL2520993 0.89 JAK2 (0.84) JAK2JAK1JAK3TYK2EPHA2
Trifluoroacetic Acid SCHEMBL4358100 0.83 JAK2 (0.58) JAK2JAK1JAK3TYK2EPHA2
Trifluoroacetic Acid SCHEMBL1074486 0.83 JAK2 (0.53) JAK2JAK1JAK3TYK2ALK
Trifluoroacetic Acid SCHEMBL1076108 0.83 JAK2 (0.53) JAK2JAK1JAK3TYK2ALK
Trifluoroacetic Acid SCHEMBL1073708 0.82 JAK2 (0.54) JAK2JAK1JAK3TYK2EPHA2
Trifluoroacetic Acid SCHEMBL1073799 0.81 ALK (0.43) JAK2JAK1JAK3TYK2ALK
Trifluoroacetic Acid SCHEMBL1075540 0.80 JAK2 (0.59) JAK2JAK1JAK3TYK2ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK JAK2 1/4885JAK1 2/4885JAK3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.